# Context Therapeutics (CNTX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/CNTX
## Company Profile
- Ticker: CNTX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 0.4658 USD
- Market cap: 222347608.34 USD
- Last updated: 2026-08-11
## Business Overview
### Solid-Tumor T-Cell Engagers
Context Therapeutics develops bispecific antibodies that bind a tumor antigen and CD3 to recruit T cells against solid tumors.
### CTIM-76
CTIM-76 targets Claudin 6 and CD3. It is the company's lead Phase 1 program in tumors expressing the developmentally restricted CLDN6 antigen.
### CT-95
CT-95 is a mesothelin-directed CD3 bispecific antibody in Phase 1 development for mesothelin-expressing solid tumors.
### CT-202
CT-202 targets Nectin-4 and CD3 and is preparing to enter first-in-human testing, adding a third tumor-associated antigen to the platform.
## Why The Stock Is Moving

As of Aug 11, 2026, CNTX closed up 2.98% at $0.4658. No new same-company headline was identified in the current news window.

## Future Catalysts

- Phase 1a interim data for CTIM-76 in June 2026.
- Phase 1 initiation for CT-202 in the third quarter of 2026.
- Phase 1a interim data for CT-95 in September 2026.

## Recent News
- 2026-08-05 20:15 EST — [Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress](https://biopharmsignal.com/news/CNTX/context-therapeutics-reports-second-quarter-2026-operating-and-pipeline-progress-4ea9f57f) — Source: Context Therapeutics
- 2026-07-10 20:05 EST — [Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/CNTX/context-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-844649bd) — Source: Context Therapeutics
- 2026-07-06 20:07 EST — [Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes](https://biopharmsignal.com/news/CNTX/context-therapeutics-added-to-russell-2000-and-russell-3000-indexes-71f8f968) — Source: Context Therapeutics
- 2026-06-15 10:30 EST — [Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76](https://biopharmsignal.com/news/CNTX/context-therapeutics-announces-positive-interim-efficacy-and-safety-results-from-c45e8d77) — Source: Context Therapeutics
- 2026-05-27 11:30 EST — [Context Therapeutics to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/CNTX/context-therapeutics-to-present-at-the-jefferies-global-healthcare-conference) — Source: Context Therapeutics